Lobbying disclosures · Lobbying report
DHR: third_quarter 2026 lobbying report
Issues pertaining to the regulation of cell and gene therapy products. Issues pertaining to the biomedical research enterprise. H.R. 8646, FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, Issues related to cell and gene therapy products at FDA.
Follow DHR- Became public
- Oct 14, 2026, 4:29 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 2:08 AM EST
Why this is connected
Legal-name match: DANAHER CORPORATION is DANAHER CORP /DE/ (https://www.sec.gov/Archives/edgar/data/313616/), differing only in punctuation, "the" or suffix spelling (Corp/Corporation).
Reported lobbying amounts
Income: $36,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/bb98967e-35c2-43f6-9be9-7f30c0638313/","filing_uuid":"bb98967e-35c2-43f6-9be9-7f30c0638313","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/bb98967e-35c2-43f6-9be9-7f30c0638313/print/","filing_document_content_type":"text/html","income":"36000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"R. Reed Skaggs, Chief Strategy and Business Officer","dt_posted":"2026-10-14T16:29:15-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"250 Massachusetts Ave. NW","registrant_address_2":"Suite 550","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":22781,"url":"https://lda.gov/api/v1/registrants/22781/","house_registrant_id":30442,"name":"LEWIS-BURKE ASSOCIATES, LLC","description":"Lobbying and Consulting Firm","address_1":"440 1st Street NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"REED SKAGGS","contact_telephone":"+1 202-289-7475","dt_updated":"2026-07-13T12:18:35.067037-04:00"},"client":{"id":73166,"url":"https://lda.gov/api/v1/clients/73166/","client_id":73166,"name":"DANAHER CORPORATION","general_description":"For-profit Company - Biomedical Products","client_government_entity":null,"client_self_select":false,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2026-05-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the regulation of cell and gene therapy products. Issues pertaining to the biomedical research enterprise.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":false},{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 8646, FY 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, Issues related to cell and gene therapy products at FDA.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152329,"prefix":"ms","prefix_display":"MS.","first_name":"ANJALI","nickname":null,"middle_name":"HELENA","last_name":"TADAVARTHY","suffix":null,"suffix_display":null},"covered_position":"Paid Intern - Washington DC Office of Senator Tina Smith","new":false},{"lobbyist":{"id":152328,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"ANTHONY","last_name":"PETERSON","suffix":null,"suffix_display":null},"covered_position":"Legislative Director, Sen. Leg. Assistant, Leg. Assistant, Leg. Correspondent/Digital Media Specialist, Staff Assistant, Intern, Congressman Peter J. Visclosky","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in DHR
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Oct 13, 2026 · disclosed Nov 5, 2026 · Dependent
Traded 7 days before earnings - Sep 25, 2026$1K–$15K
Rep. Kevin Hern (R-OK-1)
$1K–$15K · Traded Sep 2, 2026 · disclosed Sep 25, 2026 · Joint
- Sep 25, 2026$15K–$50K
Rep. Kevin Hern (R-OK-1)
$15K–$50K · Traded Aug 31, 2026 · disclosed Sep 25, 2026 · Joint
- Jul 21, 2026$1K–$15K
Sen. Alan Armstrong (R-OK)
$1K–$15K · Traded Mar 27, 2026 · disclosed Jul 21, 2026 · filed 116 days later
Committee overlap: HELP - Feb 6, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Jan 29, 2026 · disclosed Feb 6, 2026 · Spouse
- Jan 15, 2026$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Dec 18, 2025 · disclosed Jan 15, 2026 · Joint
- Jan 13, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
$1K–$15K · Traded Apr 28, 2025 · disclosed Jan 13, 2026 · filed 260 days later
- Dec 11, 2025$1K–$15K
Rep. Julie Johnson (D-TX-32)
$1K–$15K · Traded Nov 13, 2025 · disclosed Dec 11, 2025 · Joint
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.